Click on your Answer and see how it relates to your colleagues'.


The PROMISE study, published in Diabetes Technology & Therapeutics in February 2022, was completed in order to evaluate:
a. Accuracy and safety of a next generation 90-day CGM system
b. Accuracy and safety of the next-generation implantable CGM system for up to 180 days
c. People with diabetes' need of an implantable CGM system for up to 180 days
d. None of the above
Submit